Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report

World J Clin Cases. 2021 Jun 16;9(17):4373-4380. doi: 10.12998/wjcc.v9.i17.4373.

Abstract

Background: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis (CG). The cause of PL combined with CG is poorly understood, and there is currently no effective treatment. Refractory CG with upper urinary tract obstruction even requires partial or radical bladder resection.

Case summary: In this case, a patient suffering from PL with CG was treated by transurethral resection of bladder tumour (TUR-BT) and oral administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The LUTS were alleviated, and the cystoscopy results improved significantly. Immunohistochemistry showed up-regulated COX-2 expression in the epithelium of TUR-BT samples, suggesting that COX-2 may participate in the pathophysiological process of PL combined with CG.

Conclusion: We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.

Keywords: Case report; Celecoxib; Cyclooxygenase-2; Cystitis glandularis; Lower urinary tract symptoms; Pelvic lipomatosis.

Publication types

  • Case Reports